Coherus Biosciences | CHRS - Loan Capital


Coherus Biosciences reported $294.85M in Loan Capital for its fiscal quarter ending in March of 2025.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
Akebia Therapeutics USD 48.25M 609K Dec/2025
ALKERMES USD 285.82M 639K Sep/2024
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
Baxter International USD 9.47B 726M Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Coherus Biosciences USD 294.85M 2.33M Mar/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Fujifilm JPY 642.24B 70.37B Dec/2025
Gilead Sciences USD 22.14B 5M Sep/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Merck USD 39.97B 6B Sep/2025
Myriad Genetics USD 119.5M 60.2M Sep/2025
Pacira USD 372.19M 4.53M Dec/2025
Perrigo USD 3.6B 4.5M Dec/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Teva Pharmaceutical Industries USD 14.99B 1.78B Dec/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025
Xencor USD 76.48M 11.29M Dec/2025
Zoetis USD 9.04B 1.97B Dec/2025